| Journal | The Journal of pharmacology and experimental therapeutics |
| Study Type | Clinical Study |
| Population | Human participants |
CBG is increasingly used by patients for anxiety despite limited pharmacokinetic data to guide dosing or safety considerations. This study reveals unexpected brain penetration patterns and anxiogenic effects that challenge common assumptions about CBG’s therapeutic profile.
Researchers developed a sensitive analytical method to track CBG and its metabolite cyclo-CBG in male mice after intraperitoneal administration of 10 mg/kg CBG. While CBG itself showed limited brain penetration (brain-to-plasma ratio 0.26), its metabolite cyclo-CBG accumulated extensively in brain tissue (ratio 7.1), suggesting local formation. Contrary to anecdotal reports of anxiolytic effects, CBG produced anxiogenic-like behaviors at peak brain concentrations. The study was limited to male mice and a single administration route.
“This preclinical data gives me pause about CBG’s assumed safety profile for anxiety disorders. The dramatic brain accumulation of the metabolite and anxiogenic effects at therapeutic-relevant concentrations warrant careful clinical observation.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.